Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
about
Updates of mTOR inhibitorsImmunocompromised and immunocompetent mouse models for head and neck squamous cell carcinomaTherapeutic Implications for Overcoming Radiation Resistance in Cancer TherapyRapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental modelsEfficacy and comparative effectiveness of sirolimus as an anticancer drug.Mammalian target of rapamycin and head and neck squamous cell carcinomaThe mTOR inhibitor rapamycin suppresses DNA double-strand break repairmTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets.Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells.A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.Novel targeted therapies in head and neck cancer.Autophagic action of new targeting agents in head and neck oncology.Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximabmTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerBiologic therapy in head and neck cancer: a road with hurdles.mTOR co-targeting strategies for head and neck cancer therapyA phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
P2860
Q24607170-8B8A10A4-49C9-4809-8745-9D0E49576371Q26766538-B2C93D97-2ABC-49E1-AE01-8BFF1DB5B353Q26777016-4F58ABD3-18CA-4565-A600-94990FC8494DQ33649918-364D119A-B6E1-43E5-B3F3-738AF65308A5Q34163076-FE38FD59-31E0-4593-92C8-FB574E9355EEQ34188530-BACBF27F-E038-4C0F-AFB2-36B6F99C3310Q34788361-820AE22E-DC7A-44EC-A0D8-9C3D44F5511CQ34891527-08B14CF7-06D8-4956-844A-90F40D840C5CQ35027222-E68E7DE1-E3EE-459B-BB08-9E4132CAA31DQ35545852-DB8E1A25-4389-46D8-90F6-7D2D38A13E79Q36237523-F6468A17-44BA-4ABA-A18F-79D4D5292F41Q36446451-109C3D96-1A85-4AD0-93BB-BD56F4E9A0FBQ36865078-0EEAC649-3A10-4184-BE82-E4EBAA8B8902Q36879225-CA9BEEE4-C82E-4FF8-8351-612DF76B0F18Q37269265-39D9AFDE-084B-40C6-9427-8755A13856BAQ37328494-189128FF-B4E9-4749-8A4A-D9B831AA56D6Q37339508-0E8054FE-4782-45B8-AB43-FE3806E3ECEDQ37448156-46135B9F-3D6D-4C48-9262-2CDA848598A5Q37632992-73532307-5798-4656-9F71-9258E7DBA544Q37975224-015CA86C-75E4-4E86-BB50-B1A14986CD9CQ38028794-F841DDC4-D5D1-4580-B8E4-5E8BEF17CBEAQ38344592-B6D21605-74C7-4CC5-9BAE-ABA3A4F9B686Q38885166-A7053AFB-1575-408E-94DD-2A25D3548D14Q39420117-F38DD887-273A-4B7F-8F8B-9653760199D0Q39476954-E4E15C1D-7D5E-4E57-8484-A2CD4EF57921Q42213295-3EAA9FD3-2512-4B57-93F1-4A253579286AQ42363764-882E8CAD-25AC-403B-9DBF-028C64D65CF6Q42494246-937F006C-08C4-45F7-8A6D-E330ABD7CA3BQ44236729-30743084-9D6E-46CC-982F-0CA71A539204Q52627703-C101EFE5-E9FC-4FC2-BDBC-51730A5D5C8CQ57450687-E0A497EB-75AA-4239-890B-023DDDCDF28C
P2860
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@en
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@nl
type
label
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@en
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@nl
prefLabel
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@en
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@nl
P2093
P2860
P1476
Comparison of radiosensitizing ...... neck squamous cell carcinoma.
@en
P2093
Cherie-Ann O Nathan
Federico Ampil
Fleurette Abreo
Gloria Caldito
John Kai Siung Chang
Jonathan Glass
Kavita M Pattani
Oleksandr Ekshyyan
Xiaohua Rong
Youhua Rong
P2860
P304
P356
10.1158/1535-7163.MCT-08-1184
P577
2009-07-22T00:00:00Z